; (B) the location of each domestic and foreign establishment registered under section 510 of the Federal Food, Drug, and Cosmetic Act and identified in such registration as manufacturing, preparing, propagating, or compounding such critical medication or a key ingredient thereof, as well as, for each such establishment, the current and historical production thereof and the current production capacity thereof; (C) the likelihood of continued or increased production from each domestic and foreign establishment referenced in subparagraph (B), and the timeframe necessary for any increase in production, taking into account regulatory, logistical, economic, and other relevant factors; and (D) any economic, regulatory, or other impediments to domestic production thereof. (4) Timeframe for designation and reevaluation The Secretary shall— (A) determine whether to designate a critical medication under paragraph (1) not later than 90 days after the earlier of— (i) the date that such medication was first proposed by the Secretary to be a critical medication through publication in the Federal Register in accordance with subsection (a)(4)(B); or (ii) the date that such medication became a critical medication pursuant to the final determination of the Secretary in accordance with subsection (a)(1)(A); or (B) not later than March 15 each year, reevaluate in accordance with paragraph (1)(A) each designation in effect under paragraph (1)(B). (5) Public input and factors to be considered In carrying out paragraph (1), the Secretary shall— (A) consult with relevant stakeholders, including those described in subsection (a)(6)(A); (B) consider the annual threat-based review and reports referenced in and input received under subsection (a)(7)